AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Regeneron Q2 Profit Tops Estimates, Revenue Rises 3.6%
ByAinvest
Friday, Aug 1, 2025 6:59 am ET1min read
Regeneron Pharmaceuticals reported Q2 earnings of $1.392 billion, beating estimates of $8.43 per share. Revenue rose 3.6% to $3.676 billion. CEO Leonard S. Schleifer attributed the strong quarter to growth in EYLEA HD, Dupixent, and Libtayo sales, as well as multiple regulatory approvals.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported its second-quarter (Q2) 2025 earnings, with the company posting a net income of $1.392 billion, surpassing analysts' estimates of $8.43 per share. Revenue for the quarter rose 3.6% to $3.676 billion, marking a significant improvement over the previous quarter's performance.CEO Leonard S. Schleifer attributed the strong quarter to robust growth in EYLEA HD, Dupixent, and Libtayo sales, as well as multiple regulatory approvals. The company's EYLEA HD sales increased 29% to $393 million, while Dupixent global net sales rose 22% to $4.34 billion. Additionally, Libtayo's sales contributed to the overall revenue growth.
Regeneron also received several regulatory approvals during the quarter, including FDA approval for Lynozyfic (linvoseltamab) for relapsed or refractory multiple myeloma, and Dupixent for bullous pemphigoid and chronic spontaneous urticaria (CSU). These approvals are expected to drive future growth for the company.
The company's financial highlights include a 4% increase in total revenues, a 3% increase in GAAP net income, and a 12% increase in non-GAAP net income. The company also returned over $2.3 billion of capital to shareholders through share repurchases and dividends, and committed over $7 billion to U.S. manufacturing investments, capital expenditures, and business development since the start of 2025.
Looking ahead, Regeneron continues to prioritize its diverse pipeline, with approximately 45 product candidates in clinical development. The company is optimistic about the potential of its pipeline and expects additional data and regulatory milestones later this year.
References:
[1] https://finance.yahoo.com/news/regeneron-regn-q2-earnings-expect-030137811.html
[2] https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46785919/regeneron-pharmaceuticals-likely-to-report-lower-q2-earnings-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call
[3] https://www.manilatimes.net/2025/08/01/tmt-newswire/globenewswire/regeneron-reports-second-quarter-2025-financial-and-operating-results/2160685
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet